Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

A cytokine storm is a hyperinflammatory state secondary to the excessive production of
cytokines by a deregulated immune system. It manifests clinically as an influenza-like …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …

Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …

Introduction Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …

Unusually for a viral infection, the immunological phenotype of severe COVID-19 is
characterised by a depleted lymphocyte and elevated neutrophil count, with the neutrophil …

Background We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor,
for the treatment of patients admitted to hospital with COVID-19. Methods This randomised …

In patients with severe COVID‐19, acute respiratory distress syndrome (ARDS), multiple
organ dysfunction syndrome (MODS), and even mortality can result from cytokine storm …

The poor outcome of the coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, is
associated with systemic hyperinflammatory response and immunopathology. Although …